DSpace Repository

CASE SERIES: EFFICACY AND SAFETY OF HEMOADSORPTION WITH HA-330 ADSORBER IN SEPTIC PEDIATRIC PATIENTS WITH CANCER

Show simple item record

dc.contributor.author Sazonov, Vitaliy
dc.contributor.author Abylkassov, Ramazan
dc.contributor.author Tobylbayeva, Zaure
dc.contributor.author Saparov, Askhat
dc.contributor.author Mironova, Olga
dc.contributor.author Poddighe, Dimitri
dc.date.accessioned 2021-08-12T09:15:57Z
dc.date.available 2021-08-12T09:15:57Z
dc.date.issued 2021-06-11
dc.identifier.citation Sazonov, V., Abylkassov, R., Tobylbayeva, Z., Saparov, A., Mironova, O., & Poddighe, D. (2021). Case Series: Efficacy and Safety of Hemoadsorption With HA-330 Adsorber in Septic Pediatric Patients With Cancer. Frontiers in Pediatrics, 9. https://doi.org/10.3389/fped.2021.672260 en_US
dc.identifier.issn 2296-2360
dc.identifier.uri https://www.frontiersin.org/articles/10.3389/fped.2021.672260/full
dc.identifier.uri https://doi.org/10.3389/fped.2021.672260
dc.identifier.uri http://nur.nu.edu.kz/handle/123456789/5683
dc.description.abstract Background: Sepsis is a frequent cause of death in hospitalized patients and, in detail, in neonatal, pediatric, and adult intensive care units (ICUs). Severe sepsis has a very poor prognosis. Indeed, the mortality rate varies between 30 and 70% during the first 7–14 days. Despite a timely and appropriate therapy, the prognosis of severe sepsis is too often negative. Therefore, new therapeutic resources are under investigation in order to further improve prognosis. Case series: Here, we reported three septic children in whom we used extracorporeal blood purification therapy with hemoadsorption device HA330 (Jafron Biomedical Co., Ltd., China), aiming to scavenge and eliminate bacterial toxins and inflammatory mediators from the blood. Discussion and Conclusion: This small case series first showed that hemoperfusion with HA330 cartridge may be an effective and relatively safe adjunctive treatment to counterbalance the cytokine storm in septic children with hematological disorders. Further studies are needed to confirm and further support its safety and efficacy in a large number of pediatric patients. en_US
dc.language.iso en en_US
dc.publisher Frontiers Media S.A. en_US
dc.relation.ispartofseries Frontiers in Pediatrics;11 June 2021 | https://doi.org/10.3389/fped.2021.672260
dc.rights Attribution-NonCommercial-ShareAlike 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/3.0/us/ *
dc.subject Type of access: Open Access en_US
dc.subject Research Subject Categories::MEDICINE en_US
dc.subject blood purification en_US
dc.subject HA-330 adsorber en_US
dc.subject hemoadsorption en_US
dc.subject pediatric cancer en_US
dc.subject sepsis en_US
dc.title CASE SERIES: EFFICACY AND SAFETY OF HEMOADSORPTION WITH HA-330 ADSORBER IN SEPTIC PEDIATRIC PATIENTS WITH CANCER en_US
dc.type Article en_US
workflow.import.source science


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States

Video Guide

Submission guideSubmission guide

Submit your materials for publication to

NU Repository Drive

Browse

My Account

Statistics